Multiple sclerosis relapse – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:03:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Multiple sclerosis relapse – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effectiveness-of-ofatumumab-for-patients-with-relapsing-multiple-sclerosis/ Wed, 29 Apr 2026 15:01:39 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effectiveness-of-ofatumumab-for-patients-with-relapsing-multiple-sclerosis/ This clinical trial is focused on studying the long-term safety and effectiveness of a medication called ofatumumab in people with relapsing multiple sclerosis (RMS). Multiple sclerosis is a condition where the immune system mistakenly attacks the protective covering of nerves, leading to communication problems between the brain and the rest of the body. Ofatumumab is a type of medication known as a monoclonal antibody, which is designed to target specific cells in the immune system to help reduce the frequency of relapses in multiple sclerosis.

The purpose of this study is to evaluate how well ofatumumab is tolerated and how safe it is when used over a long period. Participants in the study will receive ofatumumab as an injection under the skin once every four weeks. The study will monitor participants for any side effects or changes in their health, including any changes in their laboratory test results or vital signs. The study will also track the number of relapses participants experience and any changes in their level of disability over time.

Participants will be followed for up to 240 weeks, which is about 4.5 years, to gather comprehensive data on the long-term effects of ofatumumab. The study aims to provide valuable information on the potential benefits and risks of using ofatumumab for managing relapsing multiple sclerosis, helping to inform future treatment options for this condition.

]]> Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Relapsing Multiple Sclerosis https://clinicaltrials.eu/trial/study-on-the-effects-of-a-higher-dose-of-ocrelizumab-for-adults-with-relapsing-multiple-sclerosis/ Wed, 29 Apr 2026 14:57:07 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-a-higher-dose-of-ocrelizumab-for-adults-with-relapsing-multiple-sclerosis/ This clinical trial is focused on studying the effects of a higher dose of Ocrelizumab in adults with Relapsing Multiple Sclerosis (MS). Multiple Sclerosis is a condition where the immune system mistakenly attacks the protective covering of nerves, which can lead to various neurological problems. The study aims to determine if a higher dose of Ocrelizumab is more effective than the currently approved dose in reducing the progression of disability in people with this type of MS.

Participants in the study will receive either the higher dose of Ocrelizumab, the approved dose, or a placebo. Ocrelizumab is administered as a solution for infusion, which means it is given through a vein. The study will monitor participants over a period to assess the impact of the treatment on their condition. The goal is to see if the higher dose can better prevent the worsening of symptoms compared to the standard dose.

Throughout the study, various health indicators will be tracked, including changes in brain volume, levels of certain proteins in the blood, and the number of specific immune cells. The study will also evaluate the safety of the higher dose by monitoring any side effects. This research is important for understanding how to better manage Relapsing Multiple Sclerosis and improve the quality of life for those affected by this condition.

]]> Study on Ofatumumab Levels in Breast Milk of Women with Relapsing Multiple Sclerosis https://clinicaltrials.eu/trial/study-on-ofatumumab-levels-in-breast-milk-of-women-with-relapsing-multiple-sclerosis/ Wed, 29 Apr 2026 14:28:45 +0000 https://clinicaltrials.eu/trial/study-on-ofatumumab-levels-in-breast-milk-of-women-with-relapsing-multiple-sclerosis/ This clinical trial focuses on women with relapsing forms of Multiple Sclerosis (MS), a condition where the immune system mistakenly attacks the protective covering of nerves, causing communication problems between the brain and the rest of the body. The study examines the use of ofatumumab, a medication known by the brand name Kesimpta, which is administered as a solution for injection. The purpose of the study is to measure the concentration of ofatumumab in the breast milk of women who are breastfeeding and have started or restarted treatment with this medication after giving birth.

Participants in the study will receive ofatumumab injections and provide breast milk samples at specific times to determine how much of the medication is present in the milk. The study will track the concentration of ofatumumab in breast milk over a period of 28 days after the second or any subsequent maintenance dose. Additionally, the study will monitor the health of both the mothers and their breastfed infants for up to 12 months after the mothers begin or resume treatment with ofatumumab.

The study aims to gather important information about the presence of ofatumumab in breast milk and its potential effects on breastfed infants. This information will help healthcare providers make informed decisions about the use of ofatumumab in breastfeeding women with relapsing forms of MS. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered, and it is conducted at multiple centers to ensure a comprehensive collection of data.

]]> Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-tolerability-of-ofatumumab-compared-to-a-drug-combination-for-patients-with-newly-diagnosed-relapsing-multiple-sclerosis/ Wed, 29 Apr 2026 14:27:58 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-tolerability-of-ofatumumab-compared-to-a-drug-combination-for-patients-with-newly-diagnosed-relapsing-multiple-sclerosis/ This clinical trial is focused on studying the treatment of relapsing multiple sclerosis (RMS), a condition where the immune system mistakenly attacks the protective covering of nerves, causing communication problems between the brain and the rest of the body. The study will compare the effectiveness and tolerability of a medication called ofatumumab, which is given as a monthly injection under the skin, against other first-line treatments chosen by doctors. These treatments include dimethyl fumarate, diroximel fumarate, interferon beta-1a, glatiramer acetate, teriflunomide, and peginterferon beta-1a. Some of these medications are taken orally, while others are injected.

The purpose of the study is to evaluate how well ofatumumab works compared to these other treatments in people who have recently been diagnosed with RMS and have not yet received treatment. Participants will be randomly assigned to receive either ofatumumab or one of the other treatments. The study will last for about 15 months, during which participants will have regular check-ups to monitor their health and the effectiveness of the treatment. The study will also include a group receiving a placebo, which is a substance with no active medication, to help compare the results.

Throughout the study, researchers will look at various factors, such as the number of relapses, changes in disability levels, and any new brain lesions detected by MRI scans. The goal is to determine which treatment is more effective in preventing relapses and slowing the progression of the disease. Participants will be closely monitored for any side effects or adverse reactions to ensure their safety. This study aims to provide valuable information that could help improve treatment options for people with RMS.

]]> Study on the Effects of Ozanimod in Patients with Relapsing-Remitting Multiple Sclerosis https://clinicaltrials.eu/trial/study-on-the-effects-of-ozanimod-in-patients-with-relapsing-remitting-multiple-sclerosis/ Wed, 29 Apr 2026 14:27:51 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ozanimod-in-patients-with-relapsing-remitting-multiple-sclerosis/ This clinical trial is focused on studying the effects of a medication called ozanimod in patients with relapsing-remitting multiple sclerosis (RRMS). Multiple sclerosis is a disease where the immune system mistakenly attacks the protective covering of nerves, which can lead to symptoms like fatigue, difficulty walking, and problems with vision. The purpose of this study is to evaluate how ozanimod can help limit the progression of brain damage over a period of two years in people with this condition.

Participants in the study will receive ozanimod, which is taken orally, meaning it is swallowed in pill form. The study will observe changes in the brain, such as overall brain shrinkage and specific areas like the gray matter, white matter, thalamus, and cortex. These observations will help researchers understand how the medication affects the brain and whether it can slow down the damage caused by the disease.

Throughout the study, researchers will also look at how ozanimod impacts other aspects of the participants’ lives, including their cognitive abilities, levels of fatigue, mood, and overall quality of life. This comprehensive approach aims to provide a better understanding of how the medication can improve the daily lives of those living with relapsing-remitting multiple sclerosis.

]]> Study on Ofatumumab for Patients with Relapsing Multiple Sclerosis Transitioning from Fumarate-Based Therapies or Fingolimod https://clinicaltrials.eu/trial/study-on-ofatumumab-for-patients-with-relapsing-multiple-sclerosis-transitioning-from-fumarate-based-therapies-or-fingolimod/ Wed, 29 Apr 2026 14:27:36 +0000 https://clinicaltrials.eu/trial/study-on-ofatumumab-for-patients-with-relapsing-multiple-sclerosis-transitioning-from-fumarate-based-therapies-or-fingolimod/ This clinical trial is focused on studying the effectiveness of a treatment for relapsing multiple sclerosis (RMS), a condition where the immune system mistakenly attacks the protective covering of nerves, causing communication problems between the brain and the rest of the body. The treatment being tested is called Ofatumumab, which is given as an injection under the skin using a pre-filled pen. This study is designed to evaluate how well Ofatumumab works in patients who are transitioning from other RMS treatments, specifically those based on fumarate or a medication called Fingolimod.

The purpose of the study is to assess the effectiveness of Ofatumumab in patients who have experienced breakthrough disease activity, meaning their condition worsened despite being on previous treatments. Participants will receive Ofatumumab every four weeks over a period of 96 weeks. Throughout the study, researchers will monitor the annual relapse rate, which refers to the frequency of new attacks or worsening of symptoms. Additionally, the study will track any side effects, including reactions to the injections, and any changes in laboratory or vital signs results.

The study aims to provide valuable information on the effectiveness and safety of Ofatumumab for individuals with RMS who have not responded adequately to previous treatments. By understanding how this medication works in these patients, researchers hope to improve treatment options for those living with this challenging condition.

]]> Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ocrelizumab-methylprednisolone-and-diphenhydramine-hydrochloride-in-patients-with-multiple-sclerosis/ Wed, 29 Apr 2026 14:25:41 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ocrelizumab-methylprednisolone-and-diphenhydramine-hydrochloride-in-patients-with-multiple-sclerosis/ This clinical trial is focused on studying the effectiveness and safety of a medication called Ocrelizumab in patients with Multiple Sclerosis (MS). Multiple Sclerosis is a condition that affects the brain and spinal cord, leading to a range of symptoms such as problems with vision, arm or leg movement, sensation, or balance. The study involves patients who have previously participated in a related clinical trial sponsored by the pharmaceutical company Roche.

The purpose of this study is to evaluate how well Ocrelizumab works in managing MS symptoms and its safety over time. Participants will receive the medication through an intravenous infusion, which means it is administered directly into the bloodstream. The study will monitor various aspects of the disease, including any changes in disability levels, the occurrence of relapses, and overall disease activity. Additionally, the study will use MRI scans to observe changes in the brain that are associated with MS.

Throughout the study, participants will be regularly assessed to track their progress and any side effects they may experience. The study aims to provide valuable information on the long-term use of Ocrelizumab in treating MS, helping to improve understanding of its benefits and risks for patients living with this condition.

]]>